DNA lipid complex gene delivery systems - Valentis

Drug Profile

DNA lipid complex gene delivery systems - Valentis

Latest Information Update: 21 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source; Valentis
  • Developer DSM; Valentis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis; Cystic fibrosis; Head and neck cancer; Ischaemic heart disorders; Osteoarthritis; Peripheral vascular disorders; Rheumatoid arthritis; Solid tumours; Transplant rejection

Most Recent Events

  • 19 Oct 2005 A preclinical study has been added to the Cancer pharmacodynamics section
  • 03 Apr 2001 Discontinued-II for Cystic fibrosis in USA (Inhalation)
  • 22 Jun 1999 The GeneMedicine/Megabios merged company is now called Valentis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top